Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia. Boudry A, Goursaud L, Lebon D, Dumezy F, et al. Br J Haematol 2025;207:1953-1961.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Boudry A, Goursaud L, Lebon D, Dumezy F, et al. Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia. Br J Haematol 2025;207:1953-1961.
PMID: 40903763